Objective: To review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of the fixed-dose combination (FDC) product, QTERN (dapagliflozin/saxagliptin) tablets. Data Sources: Searches of MEDLINE (1946 to July 1, 2017) were conducted using the keywords QTERN, saxagliptin, and dapagliflozin. Additional data were obtained from the prescribing information, the product dossier, and Clinicaltrials.gov. Study Selection and Data Extraction: All English language articles related to pharmacology, pharmacokinetics, efficacy, or safety of the combination therapy in human subjects were reviewed. Data Synthesis: The pharmacokinetics of saxagliptin and dapagliflozin were not affected significantly when administered as an FDC product. Saxagliptin may suppress the increased secretion of glucagon associated with dapagliflozin. The combination dapagliflozin/saxagliptin has been studied as add-on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus (T2DM). The difference in hemoglobin A 1C (A1C) between saxagliptin + dapagliflozin + metformin (triple therapy) and saxagliptin + metformin was −0.59 (95% CI = −0.81 to −0.37, P < 0.0001), and the difference between triple therapy and dapagliflozin + metformin was −0.27 (95% CI = −0.48 to −0.05, P = 0.0166). The combination was well tolerated when added to metformin. Conclusion: QTERN (dapagliflozin/saxagliptin) tablets are a reasonable option for patients with T2DM not controlled on metformin, but cost, insurance coverage, and a lackluster reduction in A1C will likely limit its use until more data regarding its effects on complications of diabetes and cardiovascular outcomes become available.
Introduction
More than 30 million Americans are living with diabetes mellitus, with type 2 accounting for up to 95% of all diagnosed cases. 1 In addition to lifestyle management through nutrition therapy and physical activity, pharmacological approaches can help achieve glycemic targets. The cornerstone of type 2 diabetes mellitus (T2DM) pharmacological management is metformin as initial therapy. A patient-centered approach is recommended to guide the choice of addon pharmacological agents, such as sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose transporter-2 (SGLT-2) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists, or basal insulin. Clinical considerations include efficacy, risk of hypoglycemia, the impact on patient weight, and potential adverse effects. 2 A comparative meta-analysis suggests that each class added to initial therapy generally lowers hemoglobin A 1C (A1C) by approximately 0.9% to 1.1%. 3 Therefore, the combination of a DPP-4 inhibitor with an SGLT-2 inhibitor has the potential to produce a meaningful reduction in A1C. 4 QTERN (dapagliflozin/saxagliptin) is a fixed-dose combination (FDC) product indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2DM who have had inadequate control with dapagliflozin or are already treated with dapagliflozin and saxagliptin. 5 Both agents exert their glucose-lowering effects through complementary mechanisms. The glucosuria produced by SGLT-2 inhibitors is associated with an increased rate of endogenous glucose production (EGP). Given that DPP-4 inhibitors inhibit glucagon secretion and reduce EGP, the combination could theoretically produce a synergistic effect on glucose lowering. 6 Saxagliptin (Onglyza) and dapagliflozin (Farxiga) were Food and Drug Administration (FDA)-approved for the treatment of T2DM on July 31, 2009, and January 13, 2014, respectively. 7, 8 Following the submission of a new drug application to the FDA on October 16, 2015 , and supplemental clinical data, QTERN (dapagliflozin/saxagliptin) was FDA approved on February 28, 2017. 9, 10 With so many options available to treat T2DM, it is important for pharmacists to understand the advantages and disadvantages of new agents. The objective of this article is to review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of QTERN (dapagliflozin/saxagliptin) tablets. It will also compare and contrast QTERN (dapagliflozin/saxagliptin) with the other available FDC SGLT-2 inhibitor and DPP-4 inhibitor, Glyxambi (empagliflozin/linagliptin).
Data Sources
A search of MEDLINE (1946 to July 1, 2017) was conducted using the terms QTERN, saxagliptin, and dapagliflozin. Saxagliptin and dapagliflozin were combined with the Boolean operator AND. All English language articles related to pharmacology, pharmacokinetics, efficacy, or safety of the combination therapy in human subjects were included. The references of included articles were searched to identify additional sources. The product dossier was obtained from the manufacturer, and additional data were obtained from the prescribing information and Clinicaltrials.gov.
Data Synthesis

Pharmacology
Glucose-lowering agents have targeted various organs, including the pancreas, liver, muscle cells, adipose tissue, small intestine, and kidney.
11 QTERN (dapagliflozin/saxagliptin) includes a combination of 2 antihyperglycemic agents to improve glycemic control in patients with T2DM: dapagliflozin, an SGLT-2 inhibitor, and saxagliptin, a DPP-4 inhibitor. 5 SGLT-2 in the proximal renal tubules is responsible for the majority of the reabsorption of filtered glucose.
12 By inhibiting SGLT-2, dapagliflozin reduces reabsorption of filtered glucose and thereby increases urinary glucose excretion. 13 Dapagliflozin can complement the mechanisms of other agents, with limited risk of hypoglycemia. 14 Incretin hormones such as GLP-1 and glucose-dependent insulinotropic polypeptide are released into the bloodstream from the small intestine in response to meals. These hormones cause insulin release from the pancreatic β cells in a glucose-dependent manner but are inactivated by the DPP-4 enzyme within minutes. GLP-1 also lowers glucagon secretion from pancreatic α cells, reducing EGP. In patients with T2DM, concentrations of GLP-1 are reduced, but the insulin response to GLP-1 is preserved. 15 As a competitive DPP-4 inhibitor, saxagliptin slows the inactivation of the incretin hormones, thereby reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with T2DM. 16, 17 Given that T2DM is associated with deterioration of pancreatic β cell function, the insulin-independent mechanism of SGLT-2 inhibitors is beneficial for patients. Clinical data suggest that SGLT-2 inhibitors are also associated with a paradoxical increase in EGP accompanied by increased plasma glucagon levels. 18, 19 Therefore, addition of a DPP-4 inhibitor, which inhibits glucagon, could theoretically block the increase in EGP and further improve the antihyperglycemic effect of an SGLT-2 inhibitor. 6 The effects of saxagliptin + dapagliflozin + metformin (SAXA + DAPA + MET; triple therapy) on counterregulatory hormones as part of Rosenstock's triple therapy study have been published. 20, 21 As part of the main study protocol, patients received a liquid meal tolerance test (MTT) at baseline and at week 24. At times 0, 30, 60, 120, and 180 minutes, blood samples were drawn, and glucose, insulin, and glucagon were measured. Patients who had MTT data available at baseline and week 24 were included in this post hoc analysis. All 3 groups experienced reductions in the glucose area under the curve between times 0 and 180 minutes (AUC 0-180min ), consistent with the results of the main study. The DAPA + MET group experienced an increase in glucagon, but the SAXA + DAPA + MET group did not. The SAXA + MET group experienced an increase in insulin, but the SAXA + DAPA + MET group did not. These results suggest that adding a DPP-4 inhibitor in combination with an SGLT-2 inhibitor suppresses both the increase in glucagon associated with SGLT-2 inhibitors and the increase in insulin associated with DPP-4 inhibitors. These pharmacodynamic effects may be beneficial in patients with type 2 diabetes.
Pharmacokinetics
The pharmacokinetics of dapagliflozin and saxagliptin were not affected clinically when administered as a FDC product and as individual tablets taken together. 5, 22 Reviews of the pharmacokinetics of saxagliptin and dapagliflozin as separate entities have been published in the Annals of Pharmacotherapy. 23, 24 The high-level pharmacokinetic properties for dapagliflozin and saxagliptin are also summarized below.
Dapagliflozin. Following oral administration of dapagliflozin, the maximum plasma concentration (C max ) is usually attained within 2 hours under fasting state. Administration of dapagliflozin with a high-fat meal decreases its C max by up to 50% and prolongs T max by approximately 1 hour. 5 The metabolism of dapagliflozin is primarily mediated by UGT1A9. Dapagliflozin is extensively metabolized to the inactive metabolite, dapagliflozin 3-O-glucuronide. Dapagliflozin and its metabolites are primarily renally eliminated. The mean plasma terminal half-life (T 1/2 ) for dapagliflozin is approximately 12.9 hours following a single oral dose of dapagliflozin 10 mg. 5 Saxagliptin. The pharmacokinetics of saxagliptin and its active metabolite, 5-hydroxy saxagliptin, were similar in healthy individuals and in patients with T2DM. The median time to maximum concentration (T max ) following the 5-mg once-daily dose was 2 hours for saxagliptin and 4 hours for its active metabolite. There was a 27% increase in the AUC of saxagliptin when given with a meal as compared with fasted conditions. 5 The metabolism of saxagliptin is primarily mediated by cytochrome P450 3A4/5 (CYP3A4/5). The active metabolite of saxagliptin is half as potent as saxagliptin. Therefore, coadministration of strong CYP3A4/5 inhibitors and inducers will alter the pharmacokinetics of saxagliptin and its active metabolite. 5 Details regarding drug-drug interactions are provided in the dosing and administration section below.
Saxagliptin is eliminated by both renal and hepatic pathways. Following a single oral dose of saxagliptin 5 mg, the T 1/2 values for saxagliptin and its active metabolite were 2.5 and 3.1 hours, respectively. 5 
Clinical Trials: Glycemic Efficacy and Safety
Separate reviews of the efficacy and safety of saxagliptin and dapagliflozin have been published in the Annals of Pharmacotherapy. 23, 24 The combination of saxagliptin and dapagliflozin has been studied in 3 trials. In 2 of the trials, the combination was added sequentially. 25, 26 In the third trial, the 2 drugs were added at the same time. 20 Details of these 3 studies are provided in Table 1 and are discussed below.
Mathieu et al 26 studied the addition of dapagliflozin to patients stable on saxagliptin plus metformin in a randomized, double-blind, phase 3 trial in patients with T2DM. Patients were mostly white, mildly obese patients with uncontrolled diabetes. However, almost half of the patients had an A1C of less than 8%. Allocation was concealed. Patients were randomized to receive either dapagliflozin 10 mg daily or placebo and were followed for 24 weeks. The addition of dapagliflozin reduced mean A1C greater than placebo (−0.82% vs −0.10%; difference = −0.72%; 95% CI = −0.97 to −0.53; P < 0.0001). Fewer patients required rescue therapy or dropped out because of lack of glycemic control in the dapagliflozin group compared with placebo (−13.6%, 95% CI = −19.4 to −7.7). However, the patients who received dapagliflozin experienced more genital infections compared with placebo (5% vs 0.6%). 25 Hypoglycemia occurred in 2 patients in the dapagliflozin group and in no patient in the placebo group.
Matthaei et al 25 studied the addition of saxagliptin to patients stable on dapagliflozin plus metformin. The patient population and methods were similar to those of Mathieu et al. 26 Patients were randomized to receive either saxagliptin 5 mg daily or placebo. The addition of saxagliptin decreased mean A1C greater than placebo (−0.51% vs −0.16%; difference = −0.35%; 95% CI = −0.52 to −0.18; P < 0.0001). There were no significant increases in adverse events (AEs). Patients in both these studies had the option to enter 28-week extension studies, the results of which have not yet been published. These studies support the safety and efficacy of triple therapy when added sequentially but did not assess the addition of saxagliptin and dapagliflozin as a FDC.
Rosenstock et al 20 conducted a multicenter, randomized, active-controlled, double-blinded study in 534 patients with poorly controlled T2DM receiving metformin as monotherapy. 20 Adult patients with an A1C of 8.0% to 12.0% who were stable on metformin monotherapy were eligible for this phase 3 study. Patients were mostly white and had a mean age of 54 years. At baseline, the mean A1C was 8.94%, and the duration of diabetes was approximately 7.6 years. However, more than 40% of patients had an A1C of 9% or greater, and there was wide variation in the duration of diabetes. Thus, this population had poorer A1C control at baseline compared with the populations in the studies by Mathieu et al and Matthaei et al. 25, 26 Patients were switched to extended-release metformin (MET) at a dose of 1500 to 2000 mg/d for the 4-week leadin period and for the duration of the trial. After the lead-in period, patients were randomized with concealed allocation to 1 of 3 treatment arms. The first group received saxagliptin 5 mg and dapagliflozin 10 mg plus MET daily (SAXA + DAPA + MET); the second group received saxagliptin 5 mg and placebo plus MET daily (SAXA + MET); and the third group received dapagliflozin 10 mg and placebo plus MET daily (DAPA + MET). Patients received 3 separate tablets, and placebos for saxagliptin and dapagliflozin were matched in appearance. The duration of the trial was 24 weeks.
Of the 639 patients who entered the 4-week lead-in period, 534 were randomized and received at least 1 dose of study medication. This group of patients comprised the efficacy analysis. SAXA + DAPA + MET resulted in a greater change in the primary outcome-the adjusted mean change from baseline in A1C at 24 weeks-compared with the other 2 arms. The difference between triple therapy and SAXA + MET was −0.59 (95% CI = −0.81 to −0.37; P < 0.0001), and the difference between triple therapy and DAPA + MET was −0.27 (95% CI = −0.48 to −0.05; P = 0.0166). The proportion of patients achieving an A1C <7% was 41% in the triple therapy group compared with 18% in the SAXA + MET group and 22% in the DAPA + MET group. AEs were common, occurring in approximately 50% of the study population. The authors only discussed AEs of special interest, which included urinary tract infections, genital infections, increase in glomerular filtration rate (GFR), fractures, pancreatitis, and cutaneous reactions. Each of these occurred at a very low incidence, so it is unclear what types of AEs comprised those in the majority of the 50% of patients who experienced at least 1 AE. Regardless, serious AEs and AEs leading to discontinuation were rare. Interestingly, urinary tract infections occurred in the SAXA + MET and the DAPA + MET groups at an incidence of approximately 5%, but rarely (0.6%) in the SAXA + DAPA + MET group. Genital infections occurred in the DAPA + MET group at an incidence of 5%, but rarely in the SAXA + MET group (0.6%) and not at all in the triple therapy group. Rohwedder et al 27 studied the relationship between the frequency of both types of infections and changes in glucose excretion. The group concluded that the 2 factors were not correlated. Thus, the reason for reduced frequency of infections in the triple therapy group remains unclear. Hypoglycemia was rare among all 3 groups (1%, with no episodes of severe hypoglycemia). 27 This trial demonstrates that the 2 agents can be added simultaneously to metformin monotherapy without compromising tolerability or safety relative to adding either agent alone. It also demonstrates that the changes in glycemic control were highest in the triple therapy group but less than the sum of each treatment arm. This is similar to another trial that studied the combination of empagliflozin and linagliptin versus each agent alone in patients with inadequate control on metformin. 28 
Additional Safety Concerns
Cardiovascular Effects. The cardiovascular effects of saxagliptin were evaluated in the SAVOR TIMI (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction) trial. 29 Patients with T2DM at high risk for atherosclerotic cardiovascular disease were randomized to receive either saxagliptin or placebo. There was no difference in the composite cardiovascular outcome. However, saxagliptin increased the rate of hospitalization for heart failure compared with placebo (3.5% vs 2.8%; hazard ratio = 1.27; 95% CI = 1.07-1.51). For every 15 patients with T2DM at risk for cardiovascular disease who receive saxagliptin versus placebo for a median of 2.1 years, one will be hospitalized for heart failure. Trials of the effects of dapagliflozin on cardiovascular outcome in patients at increased risk and of the effects on renal and cardiovascular outcomes in patients with chronic kidney disease are ongoing. 30 We were unable to identify any active or recruiting trials of the effects of the combination of saxagliptin and dapagliflozin on cardiovascular outcomes registered on clinicaltrials.gov. 31 Cancer Risk. A pooled analysis of 21 phase 2 and 3 studies of more than 9000 patients was performed to assess the risk of cancer conferred by dapagliflozin. There was no difference in the overall incidence of any malignancy. However, there were numerically more cases of bladder cancer in the patients who received dapagliflozin compared with patients who received a comparator (9 in 5936 dapagliflozin-treated patients vs 1 in 3403 comparator-treated patients; incidence rate ratio = 5.168 [95% CI = 0.677, 233.55]). 32 Case patients had risk factors for bladder cancer consistent with those in the general population. A review suggests that the increased number of cancer cases is related to early detection of preexisting cancer rather than a causal effect. 33 
Dosing and Administration
Each film-coated tablet of QTERN (dapagliflozin/saxagliptin) contains 10 mg dapagliflozin (equivalent to 12.3 mg dapagliflozin propanediol) and 5 mg saxagliptin (equivalent to 5.95 mg saxagliptin hydrochloride). The recommended dose of QTERN (dapagliflozin/saxagliptin) is 1 tablet taken orally once daily in the morning with or without food. The tablet should be swallowed whole and not be split or cut. 5 QTERN (dapagliflozin/saxagliptin) is contraindicated in patients with moderate to severe renal impairment, with end-stage renal disease, or those on dialysis. Although use may be considered in patients with hepatic impairment, the benefit-to-risk should be individually assessed in patients with severe hepatic impairment because safety and efficacy have not been studied. 5 The lack of pharmacokinetic interaction between saxagliptin and dapagliflozin was demonstrated in a drug-drug interaction study between saxagliptin and dapagliflozin. It is not recommended to coadminister QTERN (dapagliflozin/saxagliptin) with strong CYP3A4/5 inhibitors (eg, ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin), because of increased saxagliptin exposure. 5 
Place in Therapy
Inadequate glycemic control is associated with long-term complications, which can be disabling or life-threatening. These include coronary artery disease, nephropathy, neuropathy, and blindness, among other microvascular and macrovascular complications. 34, 35 Although consensus guidelines provide detailed recommendations for lifestyle management (eg, nutrition therapy and physical activity) in T2DM, glycemic treatment can help prevent or delay complications. 36 There are various drug classes that are FDA approved for use in T2DM that have unique mechanisms and are associated with advantages and disadvantages. Consensus guidelines recommend a stepwise and patientcentered approach to pharmacotherapy. Although DPP-4 inhibitors have low incidence of hypoglycemia, they are costly, and certain agents are associated with an increase in heart failure hospitalizations. 37 On April 5, 2016, the FDA added warnings about heart failure risk to labels of medications containing saxagliptin and alogliptin; of note, sitagliptin showed no increased risk for heart failure, and results for linagliptin are pending. 38 SGLT-2 inhibitors as a class have low incidence of hypoglycemia and provide weight loss and blood pressure reduction benefits but may cause genitourinary infections, polyuria, and hypotension and are costly. 39 Although the combination of an SGLT-2 inhibitor and DPP-4 inhibitor seems attractive based on the ease of oral administration, lack of hypoglycemia and weight gain, and seemingly complementary mechanisms, the A1C reduction does not appear to be additive. Triple therapy only reduced A1C by 0.27% more than MET + DAPA. Although patients in the MET + DAPA group had the highest mean A1C at baseline, one would expect to see a greater reduction in that case. When stratified by A1C, patients with higher A1C did benefit more from the interventions. 4 However, adding saxagliptin to DAPA + MET only decreased A1C by 0.16% in patients with A1C >9.0% at baseline. This may be related to the inability of DPP-4 inhibitors to inhibit EGP in the presence of significant hyperglycemia and glucosuria. The lack of an incremental benefit calls the cost-effectiveness of this combination into question.
Nonetheless, the available efficacy and safety data support QTERN (dapagliflozin/saxagliptin) as an appropriate FDC for patients who have been stabilized on both dapagliflozin and saxagliptin tablets and use as add-on therapy to metformin. QTERN (dapagliflozin/saxagliptin) is the second FDC of an SGLT-2 inhibitor and DPP-4 inhibitor to be approved by the FDA after Glyxambi (empagliflozin/ linagliptin). 40 No head-to-head trials have been conducted to compare the efficacy and safety of these FDCs. In contrast to other agents, no long-term cardiovascular outcomes studies have been published for either dapagliflozin or saxagliptin, alone or as a combination. 41, 42 There are some distinguishing characteristics between the 2 available FDCs of SGLT-2 inhibitors and DPP-4 inhibitors. QTERN (dapagliflozin/saxagliptin) should not be used if the estimated GFR (eGFR) is below 60 mL/min/1.73 m 2 , and coadministration with strong CYP3A4/5 inhibitors should be avoided. 5 As stated earlier, saxagliptin worsened heart failure outcomes in a large clinical trial, and the cardiovascular impact of dapagliflozin is unknown as we await the results of the DECLARE-TIMI58 trial. 29, 30 In contrast, Glyxambi (empagliflozin/linagliptin) can be used until the eGFR falls below 45 mL/min/1.73 m 2 , and there are no concerns with coadministration with strong cytochrome P450 3A/4 inhibitors. However, coadministration with strong inducers of P-glycoprotein or cytochrome P450 3A4 is not recommended. 43 Empagliflozin improved cardiovascular outcomes in patients with preexisting cardiovascular disease in the EMPA-REG trial, and linagliptin's impact is being evaluated in the CAROLINA study. 41, 44 These differences should be taken into account if a combination SGLT-2 inhibitor and DPP-4 inhibitor is under consideration.
FDCs can provide other benefits of medication adherence and improved clinical outcomes. 45 Patients with T2DM are particularly vulnerable to nonadherence given the complexity of the disease, range of self-care activities (eg, diet, exercise, footcare, blood glucose monitoring), and the number of medications prescribed. One study found that the odds of a patient being adherent to medication by selfreport was negatively related to the number of prescribed medications, frequency of administration, and concerns about side effects. 46 In a systematic review analyzing data from 7 studies that compared FDCs to the drugs in free combination, Hutchins et al 47 concluded that the former dosing approach is associated with a 13% higher compliance rate.
In terms of formulary considerations, neither an anticipated release date or cost data for QTERN (dapagliflozin/ saxagliptin) are available at this time. The average wholesale prices (AWPs) are $470 and $436 for a 30-day supply of dapagliflozin 10-mg tablets and saxagliptin 5-mg tablets, respectively. 2 The AWP for FDCs is often comparable to or less than the sum of 2 components; however, some insurers may prefer not to cover FDC products. 45 Given the paucity of head-to-head trials, limited long-term cardiovascular outcomes data, and high up-front costs compared with other generic alternatives, it is anticipated that the availability of QTERN (dapagliflozin/saxagliptin) will have an overall limited impact on pharmacological management of patients with T2DM.
Conclusion
Patient characteristics and preferences should be considered to help guide treatment of T2DM after metformin. QTERN (dapagliflozin/saxagliptin) is a safe and effective combination agent for patients with T2DM. The combination of these 2 agents produces antihyperglycemic effects leading to beneficial outcomes in terms of reduction in blood sugar and A1C. Triple therapy decreased the increased insulin associated with DPP-4 inhibitor use, decreased the increased glucagon associated with SGLT-2 inhibitor use, and had a lower incidence of genital infection compared with adding dapagliflozin to metformin. The combination tablet may offer a benefit in terms of adherence. However, the cost, factors related to insurance coverage, and its lackluster A1C reduction will likely limit its use. Additionally, at present, it is only FDA approved for use in patients who have inadequate control with dapagliflozin or who are already treated with dapagliflozin and saxagliptin. 5 Further research should be conducted to compare QTERN (dapagliflozin/saxagliptin) tablets as a second-line agent to other second-line therapies and study the effect of the combination product on long-term outcomes, including complications of diabetes and cardiovascular events.
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